Cambridge, UK and Montreal, Canada, November 24, 2025 —BioTryp Therapeutics (BIT), a University of Cambridge spin-out company, and Intellisyn Pharma (ISN), a Montreal based preclinical drug discovery research company, are pleased to announce they are receiving advisory services and funding of up to CA$200k from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), alongside £300k from Innovate UK, to support a collaborative research and development project. This support will enable a collaborative R&D project that leverages ISN’s preclinical drug discovery expertise to accelerate BIT’s work on developing novel small molecule anti-biofilm therapies for bacterial infections.

Based on years of research at the University of Cambridge, BIT is developing novel treatments for tackling infections, with a particular focus on preventing the recurrence of hard-to-treat bacterial infections. Its initial target indication is urinary tract infections, which affect over 400 million people worldwide annually, with high recurrence rates. Infection recurrence is driven by the formation of bacterial biofilms in the urinary tract, which protect the constituent pathogens from both antibiotic therapy and the host immune system. By inhibiting the formation of these biofilms, BIT’s novel therapies will support infection eradication as well as help prevent recurrence, creating a new paradigm of treatment for these common infections.

BIT has already been working with the ISN team to identify a lead chemical series of candidate compounds, based on hit compounds previously identified. The NRC IRAP and Innovate UK support will fund a 1-year programme of research progressing BIT’s compounds into the lead optimisation stage led by ISN. Compounds will be designed and synthesised utilising ISN’s extensive background know-how, IP and machine learning algorithms, and sent to BIT for testing via their assays, in an iterative process to progress the work towards the identification of lead candidates.

The project will benefit both the UK and Canadian biotech ecosystems, supporting the development of novel therapeutics and innovative drug discovery methodologies across the two countries. In the longer term, the development of such anti-biofilm therapies will be crucial to address the fight against antibiotic resistant infections, and to support antibiotic stewardship efforts, benefiting patients and healthcare systems across the globe.

About BioTryp Therapeutics: BIT is a Cambridge (UK) based biotech that is developing novel small molecule therapies against bacterial infections. It is focused on inhibiting the formation of bacterial biofilms, a major cause of intractable and recurrent bacterial infections, and is targeting urinary tract infections as its first indication. BIT is currently a pre-seed stage company, and is in the process of seeking a seed investment round.

About Intellisyn Pharma (an X-Chem company): ISN is a preclinical drug discovery research company. Its laboratories are in Montreal Canada, and it collaborates on projects with startups, biotechs, and pharma companies from around the world. ISN brings medicinal, synthetic, and analytical chemistry expertise into the consortium. ISN has drug discovery know-how and experience around advancing hits and leads into drug candidates, including more than ten past research collaborations resulting in drug candidates.

X-Chem’s DNA-encoded library complements Charles River’s discovery expertise to accelerate hit identification

WILMINGTON, Mass., October 20, 2025 — Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel therapeutics. This partnership enables Charles River clients to access X-Chem’s DEL platform, which features a proprietary library of over 15 billion compounds.

The collaboration combines Charles River’s in-house protein production and downstream assay development, along with decades of hit ID expertise, with X-Chem’s industry-leading DEL platform, creating a seamless workflow from hit identification to Hit-to-Lead optimization. Charles River has a broad suite of hit ID services that can deliver high-quality, validated hit compounds for drug discovery projects. With this complete offering, these designs and approaches will deliver the most impactful hits to support biopharma research goals and drug development plans.

“X-Chem’s DEL technology is a powerful addition to our Hit ID Toolbox,” said Chris Barnes, Executive Director & Head, Small Molecule Drug Discovery at Charles River. “By combining our deep expertise in early drug discovery and existing hit ID suite of capabilities with X-Chem’s innovative screening platform, we can offer our clients even more flexibility in their hit-finding strategies, shaping this important first-step in their discovery programs.”

X-Chem’s DEL platform is one of the most proven and widely adopted in the industry, supporting hundreds of discovery programs across a broad range of target classes. Built on more than 15 years of refinement, X-Chem’s libraries comprise billions of high-quality, lead-like compounds designed for meaningful structure–activity exploration. The platform integrates advanced selection methodologies with robust data analysis to deliver enriched, interpretable results that accelerate early discovery.

“Partnering with Charles River extends the reach of our DEL platform to more research teams worldwide,” said Matt Clark, President & CSO at X-Chem. “Our shared goal is to make data-driven decision-making in early discovery more accessible, helping scientists see clearer paths forward, faster.”

The collaboration demonstrates both companies’ commitment to innovation, flexibility, and client success, providing a scalable solution for biotech and pharmaceutical organizations aiming to accelerate their drug discovery programs.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

About X-Chem

X-Chem is a data-driven drug discovery company transforming how scientists find and advance small-molecule therapeutics. Combining the power of DNA-encoded library (DEL) screening with medicinal chemistry expertise and deep data analytics, X-Chem uncovers high-quality chemical starting points and accelerates their evolution into optimized leads. The company partners with pharmaceutical and biotechnology organizations worldwide to deliver insight, speed, and confidence across the discovery continuum. Learn more at www.x-chemrx.com.

Intersection of best-in-class DEL, medicinal chemistry and innovative computation sciences launches era of high-throughput insights for drug discovery.

Waltham, MA – September 23, 2025 –X-Chem, a global leader in data-driven drug discovery, today announced the launch of chemomics: a transformational framework that harnesses the full scale of DNA-encoded library (DEL) technology with computational sciences and AI/ML to extract years’ worth of structure-activity relationship (SAR) insights, generate highly predictive models, and unveil a diversity of starting points.  Chemomics uniquely equips discovery programs at their inception with an unprecedented data foundation – empowering teams to reach clinical candidates with transformative speed and confidence.

Chemomics is built on X-Chem’s high signal-to-noise DEL technology, delivering reliable data at true omics scale. Rather than treating DEL as a one-step screen, chemomics establishes a discovery framework that pairs billions of high-quality data points with advanced modeling, design, and analysis — driving predictive insights that fuel actionable, data-grounded decisions earlier.

Chemomics emerged from X-Chem’s drive to unlock the true value of DEL, moving beyond hit lists to reveal the depth of information contained in billions of data points. It addresses the longstanding need for defensible data and clear rationale in decision-making. The approach also has the advantage of transparency – with no “black box” – and hypotheses confirmed through high-throughput synthesis and testing. Chemomics provides actionable insights earlier in discovery, helping teams make confident decisions with speed and clarity.

“The real promise of chemomics is its impact to redefine small molecule drug discovery, enabling unprecedented knowledge building by leveraging billions of data points. Our mission is to be the partner organization of choice, making a difference in bringing life-changing therapies closer to patients,” said Karen Lackey, CEO of X-Chem.

Through DEL-ML, pharmacophore modeling, and SAR analysis, chemomics gives discovery teams practical tools to recognize meaningful trends and guide molecule design. Built on years of investment in high signal-to-noise DEL technology, chemomics makes this unprecedented scale of data meaningful. This gives discovery teams confidence in their path forward and marks a new era of discovery powered by DEL’s unprecedented data dimensions.

X-Chem will present chemomics during Discovery on Target this week in Boston. Attendees can visit Booth #303 in the exhibit hall and join the chemomics launch reception on September 24 from 5:00 to 7:00 p.m. at The Fens, Boston Sheraton.

About X-Chem

X-Chem is redefining small molecule drug discovery through a powerful combination of computational sciences, discovery chemistry and data-driven insight. As the pioneer and global leader in DNA-encoded library (DEL) technology, X-Chem provides the foundation for smarter hit identification, accelerated lead progression and greater confidence in early discovery. X-Chem partners globally to turn complex discovery challenges into actionable solutions. Learn more at www.x-chemrx.com.

Media Contact:

Alli Cooke
Alli.Cooke@llyc.global
616.258.5769

MONHEIM, Germany and Waltham, Mass. , Aug. 21, 2025 — Cube Biotech, a pioneer in membrane protein stabilization and purification, and X-Chem, the global leader in DNA-Encoded Library (DEL) technology and data-driven drug discovery, are proud to announce the successful conclusion of Project DEL-MP. Project DEL-MP was a collaborative initiative demonstrating that copolymer-stabilized membrane proteins are not only suitable for DEL screening, they also open up completely new possibilities for even the most challenging targets.

The groundbreaking project combined Cube Biotech’s proprietary NativeMP™ copolymer technology — which enables the stabilization of functional membrane proteins in near-native conformations — and X-Chem’s world-class DEL platform and expertise in complex target screening. As a result, new avenues are now open for drug discovery against some of the most challenging targets in biomedical research.

“For years, the field has questioned whether DEL screening could be extended to membrane proteins,” said Barbara Maertens, COO and co-founder of Cube Biotech. “With Project DEL-MP, we’ve proven that not only is it possible — it’s optimal. NativeMP™ preserves native conformation, protein functionality, and accessibility of extracellular pockets — a trifecta for meaningful hit discovery.”

“Membrane proteins are some of the most important targets in drug discovery, yet they have been among the most difficult to screen effectively,” said Matt Clark, CSO of X-Chem. “By combining Cube Biotech’s NativeMP™ technology with X-Chem’s DEL screening platform, we have shown that high-quality, data-driven discovery is now possible for these challenging targets. This collaboration validates a new path forward, one that expands the impact of DEL and opens opportunities for innovation across many therapeutic areas.”

About Project DEL-MP

DEL-MP is a joint proof-of-concept and platform validation program designed to:

• Demonstrate robust DEL hit discovery against selected membrane proteins targets from different classes, and stabilized in a subset of different NativeMP™ copolymers
• Benchmark NativeMP™ proteins, including GLP1R, EGFR, TNF, P2YR11 and P2X4, revealed highly productive DEL screen readouts with enriched, target-selective compounds suitable for off-DNA synthesis and assays, independent of type NativeMP™ copolymers used for stabilization
• Demonstrate seamless automation compatibility for scalable DEL screening workflows using high-throughput instrumentation

Results from feasibility experiments, conducted on X-Chem’s screening platform, show promising results for NativeMP™-stabilized membrane protein targets — maintaining binding competency and structural fidelity over extended incubation periods.

About Cube Biotech — Pioneering Protein Technologies to Enable Drug Discovery

Cube Biotech specializes in the purification, stabilization, and functional screening of membrane proteins, offering solutions that power drug discovery campaigns around the globe — for the first time, also as a fully automated workflow. With the NativeMP™ copolymer technology, Cube enables native-like solubilization of even the most fragile targets — including GPCRs and multi-pass transporters — without the use of harsh detergents.

Cube Biotech, with the strategic backing of ARCHIMED, is committed to advancing the full protein research value chain — from discovery to delivery.

Learn more: www.cube-biotech.com

About X-Chem

X-Chem is a global leader in data-driven drug discovery, partnering with biopharma innovators to tackle the most challenging targets. Its integrated platform combines DEL screening, medicinal chemistry and advanced data analytics to uncover deeper insights, reveal untapped opportunities and accelerate the delivery of breakthrough small-molecule therapeutics.

Discover what’s possible at www.x-chemrx.com.

New leaders join X-Chem to support operational excellence and partner success across data-driven discovery programs.

Waltham, MA – June 17, 2025 – X-Chem, a global leader in data-driven drug discovery and DNA-encoded library (DEL) technology, today announced the appointments of Stephen Fair as Chief Financial Officer and Maureen Hart as Senior Vice President of Human Resources, expanding the company’s leadership team to support operational growth and discovery partnerships.

“Stephen and Maureen bring complementary strengths that will help propel X-Chem into its next phase,” said Karen Lackey, CEO of X-Chem. “Stephen’s strategic financial leadership and Maureen’s track record in building high-performing organizations are critical as we deepen partnerships and deliver on our mission to transform drug discovery.”

Stephen Fair brings nearly two decades of strategic finance and operational leadership across discovery-focused biotech and pharmaceutical companies. Most recently, he served as Senior Vice President of Finance at Abata Therapeutics, where he led financial strategy and operations. He previously held senior finance roles at FogPharma, Agios Pharmaceuticals and Merrimack Pharmaceuticals. Stephen earned his B.A. in Economics from Yale University and his MBA from Stanford University.

Maureen Hart brings extensive human resources leadership experience across the pharmaceutical, biotech, and healthcare industries. She has supported global teams across North America, Europe and Asia, with a focus on scaling organizations and enabling high-performing cultures. Most recently, she led HR for WuXi Biologics U.S., where she guided the company’s growth from 50 to 500 employees and drove key initiatives in talent acquisition, employee relations and organizational development. Prior to WuXi, Maureen held senior HR leadership roles at Shire and athenahealth.

About X-Chem

X-Chem is redefining small molecule drug discovery through a powerful combination of computational sciences, discovery chemistry and data-driven insight. As the pioneer and global leader in DNA-encoded library (DEL) technology, X-Chem provides the foundation for smarter hit identification, accelerated lead progression and greater confidence in early discovery. X-Chem partners globally to turn complex discovery challenges into actionable solutions. Learn more at www.x-chemrx.com.

Milan, Italy and Waltham, MA, USA, May 8, 2025 – Axxam S.p.A., a leading provider of integrated early discovery services, and X-Chem, Inc., a leader in DNA-Encoded Library (DEL) screening and innovative chemistry technologies, are pleased to announce a collaboration aimed at expanding the range of early drug discovery solutions offered to pharmaceutical and biotech companies, as well as academic institutions, worldwide.

This joint initiative stems from a shared commitment to tackling the growing challenge of undruggable or difficult-to-drug targets. By combining Axxam’s deep expertise in biology and comprehensive compound profiling with X-Chem’s high-performance DEL technology, the collaboration offers a more integrated and versatile screening portfolio designed to uncover novel hits across a broad spectrum of target classes.

“In a landscape where many therapeutic targets remain elusive using traditional approaches, it is critical to explore multiple discovery avenues in parallel,” said Ciriaco Maraschiello, CEO of Axxam. “Partnering with
X-Chem broadens the panel of possibilities for our clients within the framework of Axxam’s Early Drug Discovery process from Target to Lead.”

DEL screening enables the rapid interrogation of vast chemical spaces – often exceeding billions of compounds – within a single experiment. As part of the collaboration, DEL screening will be offered both as a standalone screening option and as a complementary strategy to Axxam’s existing screening technologies.

“Collaborations like this are essential to advancing discovery against the most challenging targets,” said Karen Lackey, CEO of X-Chem. “By integrating our DEL capabilities with Axxam’s biological expertise, we are creating a more powerful and flexible screening toolkit; one that gives researchers a real edge in the earliest, most critical stages of drug development.”

Together, Axxam and X-Chem are committed to offering a broader and more flexible drug discovery engine, tailored to the unique challenges of each target and therapeutic area.

About Axxam S.p.A.
Axxam S.p.A. is a leading provider of integrated discovery services across the life sciences industry. Within the drug discovery disciplines, we support pharma, biotech companies, start-ups, patient foundations as well as academic groups in their journey from hit identification to lead generation, regardless of the therapeutic area and target class. Our services include assay development, high-throughput screening, using either Axxam’s high quality compound collections (synthetic and natural) or those provided by clients, hit validation, hit-to-lead and compound management. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries. For more infomation, visit www.axxam.com.

About X-Chem, Inc.

X-Chem is a pioneer in data-driven small molecule drug discovery. By integrating DNA-encoded library (DEL) technology, artificial intelligence, and medicinal chemistry, X-Chem accelerates the path from target to clinical candidate. With a proven track record across complex targets and therapeutic areas, X-Chem delivers smarter hits, faster timelines, and reduced early-stage risk for pharmaceutical and biotech partners. Learn more at www.x-chemrx.com.

Waltham, MA, April 30, 2025 – X-Chem, a global leader in DNA-encoded library (DEL) technology and data-driven drug discovery, has announced an expanded collaboration with Orion Pharma. The agreement builds on an existing relationship and now extends the partnership from hit identification through to candidate selection. Under a new Technology Access Agreement, Orion will utilize X-Chem’s integrated discovery capabilities, including DEL screening, AI-driven hit triage, and medicinal chemistry support, to drive multiple early-stage programs forward.

This expanded engagement reflects years of collaboration and trust between the two companies. Through previous work together, X-Chem has delivered high-value insights and differentiated chemical matter to Orion’s discovery teams. The renewed commitment is a strategic step forward in advancing small molecule discovery with greater efficiency and precision

“X-Chem’s flexible business model is enabling us to evaluate both new targets and revisit existing programs with enhanced tools,” said Heikki Käsnänen, Head of Molecular Prospecting and Modeling at Orion Pharma. “We are applying their DEL-based screening technologies, as well as their expertise in AI and computational chemistry, to explore alternative routes for optimization. This approach is further supported by synthetic and medicinal chemistry to expand hit series and advance toward lead optimization.”

X-Chem’s platform combines advanced DEL capabilities with ArtemisAI, its proprietary artificial intelligence engine trained on the world’s largest DEL datasets. Together with in-house computational and medicinal chemistry teams, the company helps partners make informed decisions earlier in the discovery process, reducing risk and improving outcomes.

“Our goal is to empower innovative companies like Orion to efficiently identify and progress high-quality drug candidates,” said Karen Lackey, CEO at X-Chem. “This expanded partnership reflects a strong foundation of trust and a shared commitment to overcoming complex challenges in early discovery. By aligning our scientific expertise, we can help Orion move from hit to candidate with speed and confidence.”

The collaboration reinforces X-Chem’s position as a discovery partner with capabilities that extend well beyond traditional screening, offering end-to-end discovery solutions designed to accelerate success in small molecule drug discovery.

About X-Chem 
X-Chem is a pioneer in data-driven small molecule drug discovery. By integrating DNA-encoded library (DEL) technology, artificial intelligence, and medicinal chemistry, X-Chem accelerates the path from target to clinical candidate. With a proven track record across complex targets and therapeutic areas, X-Chem delivers smarter hits, faster timelines, and reduced early-stage risk for pharmaceutical and biotech partners. Learn more at www.x-chemrx.com.

About Orion Pharma 
Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion’s net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion’s A and B shares are listed on Nasdaq Helsinki. Learn more at www.orionpharma.com.

AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally available host-targeted broad-spectrum medical countermeasures

Host-directed antiviral drugs have the potential to enhance the immune response to viruses from a range of viral families

Tonix was awarded a contract with the U.S. Department of Defense for up to $34 million for the accelerated development of its host-directed broad-spectrum antiviral program TNX-4200

CHATHAM, N.J., October 8, 2024 (GLOBE NEWSWIRE) – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it has entered into an AI and ML research collaboration with X-Chem, Inc. (X-Chem), a leader in small molecule drug discovery, to accelerate development of Tonix’s oral broad-spectrum antivirals.

Tonix’s TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families. As previously disclosed, Tonix entered into a contract with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA) for up to $34 million to advance the development of Tonix’s TNX-4200 broad-spectrum oral antiviral program for medical countermeasures, including an Investigational New Drug (IND) submission and a first-in-human Phase 1 clinical study.

“We are excited to enter into this research collaboration with X-Chem, which we believe will expand our capabilities, and deepen our understanding of host-targeted small molecule therapeutics for a variety of targets,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “With the support of X-Chem’s drug discovery AI/ML technology, we expect to optimize the physicochemical properties, pharmacokinetics, and safety attributes of our drug candidates.”

“We are excited to partner with Tonix in their pursuit of such important programs in human health, at the intersection of laboratory and in silico technology. This collaboration highlights how integrative work continues to leverage the creation of target-specific high-quality data to drive AI drug discovery.” said Erin Davis, Ph.D., Chief Technology Officer of X-Chem.

The DTRA contract awarded to Tonix to help fund and accelerate the development of the Company’s lead oral host-directed TNX-4200 broad-spectrum antiviral program. The TNX-4200 program aims to reduce viral load and to allow the adaptive immune system to alert the other arms of the immune system to mount a protective response. Tonix plans to leverage previous research on phosphatase inhibitors to optimize lead compounds for therapeutic intervention of biothreat agents.

For the oral broad-spectrum antiviral programs, including TNX-4200, Tonix is utilizing its state-of-the-art research laboratory capabilities, including a Biosafety Level 3 (BSL-3) lab and an Animal Biosafety Level 3 (ABSL-3) facility at its research and development center (RDC) located in Frederick, Md., as well as experienced personnel in-house. The RDC is located in Maryland’s ‘I-270 biotech corridor’ and is close to the center of the U.S. biodefense research community.

About X-Chem, Inc.
X-Chem, Inc. is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology and its integration with proprietary AI technology and computational sciences, X-Chem can accelerate all steps in the discovery process. The company leverages its unique AI/ML approach, market-leading DEL platform, and computationally-driven medicinal chemistry expertise to discover novel small molecule leads against challenging, high-value therapeutic targets. Integrated with X-Chem’s extensive chemistry and computational technologies, project teams can deliver clinical candidates with unmatched speed. X-Chem also provides libraries, reagents, and informatic tools to allow DEL operators to get the most of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI and extensive data packages.

Further information about X-Chem can be found at www.x-chemrx.com.

Tonix Pharmaceuticals Holding Corp.^*
Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in October of 2024 for TNX-102 SL, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL was generally well tolerated in the Phase 3 program. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix recently announced the U.S. Department of Defense (DoD), Defense Threat Reduction Agency (DTRA) awarded it a contract for up to $34 million over five years to develop TNX-4200 small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. The company’s Good Manufacturing Practice (GMP)-capable advanced manufacturing facility in Dartmouth, MA was purpose-built to manufacture TNX-801 and the GMP suites are ready to be reactivated in case of a national or international emergency. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

WALTHAM, Mass.; Sept. 17, 2024 (Business Wire) – X-Chem, a global leader in innovative drug discovery services, announces the achievement of a drug discovery milestone, under its collaboration agreement with AstraZeneca. Working together, the companies utilized X-Chem’s DNA-encoded chemical library (DEL) screening platform to identify hits for a target of interest to AstraZeneca. The resulting hits led to a candidate compound poised for clinical study, representing a milestone under the companies’ collaboration agreement.

“We are very pleased that our colleagues at AstraZeneca have attained this important achievement,” said X-Chem CSO Matt Clark. “The fact that AstraZeneca was able to move so quickly from the hit discovered at X-Chem to a candidate molecule is a testament to their hard work and dedication, and to the quality of the hit our DEL platform yielded. Compounds with good efficiency metrics make great starting points for medicinal chemistry campaigns.”

About X-Chem
X-Chem, Inc. is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform and medicinal chemistry expertise to discover novel small molecule leads against challenging, high-value therapeutic targets. Integrated with X-Chem’s extensive chemistry and computational technologies, project teams can deliver clinical candidates with unmatched speed. X-Chem’s advanced proprietary artificial intelligence (AI) technology and computational sciences accelerate all steps in the process. X-Chem also provides libraries, reagents, and informatic tools to allow DEL operators to get the most of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI and extensive data packages.

WALTHAM, Mass.; Sept. 5, 2024 – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused on accelerating early-stage drug discovery.

X-Chem’s DEL technology streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds, identifying potential start points with high efficiency and precision.

In partnership with Evotec’s screening platforms and capabilities, X-Chem is providing access to its DEL technology, including DELflex, a traditional experimental DEL solution, and HITMiner, a machine learning solution, leveraging high quality experimental DEL data to deliver optimal drug intervention starting points for innovative biological targets.

“Partnerships to access best-in-class platforms are the way forward to address the complexity in drug discovery,” said Karen Lackey, CEO of X-Chem. “This collaboration highlights our commitment to partner with leading research organizations, like Evotec, to make DEL screening services more accessible.”

“We are pleased to collaborate with X-Chem and to leverage their leading DEL platform and capabilities,” said Craig Johnstone, Chief Operating Officer of Evotec. “X-Chem’s expertise in DEL, combined with their advanced data-mining solutions, provides us with access to an additional tool to tackle innovative and difficult biological targets.”

About X-Chem
X-Chem, Inc. is a leader in small molecule discovery science, providing pharmaceutical and biotechnology companies with a complete, seamless solution for screening, hit validation and lead optimization. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to rapidly screen billions of diverse drug-like molecules to discover novel small molecule leads against challenging, high-value therapeutic targets. In house hit-to-lead and lead optimization services driven by AI and physics-based modeling enable clients to progress their compounds directly in-house from hit all the way through to candidate nomination. Our well-proven expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery in a deeply integrated technology-driven platform.

About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com.